A new mouse esophageal cancer cell line (mEC25)‐derived pre‐clinical syngeneic tumor model for immunotherapy
Authors:
Open Access
- 8 June 2020
- journal article
- letter
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 40 (7) , 316-320
Abstract
Click on the article title to read more.Keywords
Funding Information
- National Natural Science Foundation of China (81772957)
- National Natural Science Foundation of China (81772957)
This publication has 14 references indexed in Scilit:
- Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?Cancer Communications, 2019
- Precision medicine becomes reality—tumor type‐agnostic therapyCancer Communications, 2018
- Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trialThe Lancet Oncology, 2017
- Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimensNature Protocols, 2017
- Immune suppressive mechanisms in the tumor microenvironmentCurrent Opinion in Immunology, 2016
- Fibroblast Growth Factor Receptor 2–Positive Fibroblasts Provide a Suitable Microenvironment for Tumor Development and Progression in Esophageal CarcinomaClinical Cancer Research, 2009
- Association between duodenal contents reflux and squamous cell carcinoma--establishment of an esophageal cancer cell line derived from the metastatic tumor in a rat reflux model.2007
- Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the EsophagusJournal of Clinical Oncology, 2005
- Oral Cavity and Esophageal Carcinogenesis Modeled in Carcinogen-Treated MiceClinical Cancer Research, 2004
- Esophageal cancer: results of an American College of Surgeons patient care evaluation study1Journal of the American College of Surgeons, 2000